Bill
HD 4196
Massachusetts pilot program would legalize supervised medical psilocybin use for qualifying patients, advancing therapeutic research while creating potential federal-state legal conflicts.
HD 4196 would establish a pilot program in Massachusetts allowing regulated access to psilocybin (a controlled psychoactive compound found in certain mushrooms) under medical supervision. The program would create a framework for licensed facilities to administer psilocybin to qualifying patients for therapeutic purposes, likely focusing on treatment-resistant conditions. This represents a shift from federal prohibition toward state-level decriminalization and medical research.
Psilocybin research has shown promise in clinical studies for treating depression, anxiety, PTSD, and end-of-life distress, particularly in treatment-resistant cases where conventional therapies fail. A pilot program would allow Massachusetts to gather safety and efficacy data while potentially providing therapeutic access to patients before federal rescheduling occurs. This positions the state as a leader in psychedelic-assisted medicine while creating a template for other states.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
